A Study to evaluate the effectiveness and safety of Pazopanib in a real world scenario in patients with advanced stage of renal cell carcinoma.

Phase 4

Conditions: Health Condition 1: null- patients with advanced or metastatic RCCof any histology who are treated according to local practices and treated for the first time withpazopanib

Recruitment & Eligibility

Inclusion Criteria

1-Documented diagnosis of advanced or metastatic RCC of any histology and treated

according to local practice and treated with pazopanib.

2-Clinical decision made to initiate new treatment with pazopanib or at least 15 days prior to

enrollment in the study.

3-Patients naÃ¯ve to any prior anti-VEGF therapy (prior immunotherapy including cytokines

are allowed).

4-Patients who provide written informed consent according to local guidelines.

-Note: Patients will be allowed to participate in other interventional clinical studies

5-Before starting pazopanib therapy (except trials involving VEGF-TKI treatments

where the patient is randomized/included into the VEGF-TKI arm).

6-During the course of the study as long as the therapy is not a VEGF-TKI.

Exclusion Criteria

1-Prior treatment with VEGF-TKI before starting pazopanib therapy

2-Life expectancy < 12 weeks based on the Treating Physicianâ??s assessment.

Primary Outcome Measures

Name	Time	Method
To describe the clinical effectiveness of pazopanib in the real-life setting in patients naÃ¯ve <br/ ><br>to VEGF-TKI therapy based on the proportion of patients remaining progression free at <br/ ><br>12 months.Timepoint: To describe the clinical effectiveness of pazopanib in the real-life setting in patients naÃ¯ve <br/ ><br>to VEGF-TKI therapy based on the proportion of patients remaining progression free at <br/ ><br>12 months.

Secondary Outcome Measures

Name	Time	Method
To describe other clinical effectiveness factors for pazopanib. <br/ ><br>Overall response rate (ORR) at 12 months. <br/ ><br>Progression-free survival (PFS) at end of study (EOS). Overall survival (OS) at EOS. <br/ ><br>Response (ORR and progression-free (PF) response) according to Memorial Sloan- <br/ ><br>Kettering Cancer Center (MSKCC)/Heng criteria and age category. <br/ ><br>To assess the safety and tolerability of pazopanib at 12 months. <br/ ><br>Timepoint: Outcomes will be assessed at 3 months, 9 months, 12 months and at the end of the study around 30 months